Savannah Demko

In a video interview, James Song, MD, FAAD, Co-CMO, director of clinical research at Frontier Dermatology in Mill Creek, Washington, spoke about updates in the pediatric psoriasis space presented at Maui Derm 2026.

In this video, James Song, MD, FAAD, Co-CMO, spoke about whether early intervention in psoriasis can lead to better treatment outcomes, a topic he presented at Maui Derm 2026.  

In this video, James Song, MD, FAAD, Co-CMO, director of clinical research at Frontier Dermatology in Mill Creek, Washington, discussed studies presented at Maui Derm 2026 that examined high-impact psoriasis sites.  

In a video interview, James Song, MD, FAAD, Co-CMO, discussed a presentation from Maui Derm 2026 in which he spoke about therapies in the pipeline for psoriasis.

Linda Stein Gold, MD, director of dermatology clinical research and division head of dermatology at Henry Ford Health System, discussed some “exciting talks” from Maui Derm 2026 that focused on oral agents for psoriasis.Although there’s currently an “unmet need for the oral treatment of psoriasis,” two oral TYK2 inhibitors and an oral peptide are showing

CHICAGO — Citrullinated protein-targeted chimeric antigen receptor regulatory T cells showed a promising safety profile in highly refractory patients with rheumatoid arthritis, according to phase 1 data presented at ACR Convergence 2025. This novel therapy known as SBT777101, an autologous regulatory T-cell (Treg) product transduced with a CAR specific for citrullinated proteins, also

CHICAGO — In this video interview with Healio, Micaela F. Bayard, MD, discussed the use of GLP-1 receptor agonists in treating patients with rheumatoid arthritis.

SAN DIEGO — Quantitative magnetic resonance cholangiopancreatography may help assess changes in the biliary tree and aid monitoring of patients with primary sclerosing cholangitis, according to research presented at The Liver Meeting.Although quantitative magnetic resonance cholangiopancreatography (MRCP) has potential in objectively monitoring primary sclerosing cholangitis (PSC),

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.“In my mind, these data really establish T-DXd [Enhertu; AstraZeneca, Daichii Sankyo] as standard of care, not just for systemic disease in

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.The study showed the benefit of integrating ovarian function suppression with adjuvant endocrine therapy in premenopausal women with HR-positive, HER2-postive breast cancer.